Allogeneic V gamma 9V delta 2 T-Cell Therapy Promotes Pulmonary Lesion Repair: An Open-Label, Single-Arm Pilot Study in Patients With Multidrug-Resistant Tuberculosis

Juan Liang,Liang Fu,Man Li,Yuyuan Chen,Yi Wang,Yi Lin,Hailin Zhang,Yan Xu,Linxiu Qin,Juncai Liu,Weiyu Wang,Jianlei Hao,Shuyan Liu,Peize Zhang,Li Lin,Mohammed Alnaggar,Jie Zhou,Lin Zhou,Huixin Guo,Zhaoqin Wang,Lei Liu,Guofang Deng,Guoliang Zhang,Yangzhe Wu,Zhinan Yin

DOI: https://doi.org/10.3389/fimmu.2021.756495

IF: 7.3

2021-01-01

Frontiers in Immunology

Abstract:The WHO's "Global tuberculosis report 2020" lists tuberculosis (TB) as one of the leading causes of death globally. Existing anti-TB therapy strategies are far from adequate to meet the End TB Strategy goals set for 2035. Therefore, novel anti-TB therapy protocols are urgently needed. Here, we proposed an allogeneic V gamma 9V delta 2 T-cell-based immunotherapy strategy and clinically evaluated its safety and efficacy in patients with multidrug-resistant TB (MDR-TB). Eight patients with MDR-TB were recruited in this open-label, single-arm pilot clinical study. Seven of these patients received allogeneic V gamma 9V delta 2 T-cell therapy adjunct with anti-TB drugs in all therapy courses. Cells (1 x 10(8)) were infused per treatment every 2 weeks, with 12 courses of cell therapy conducted for each patient, who were then followed up for 6 months to evaluate the safety and efficacy of cell therapy. The eighth patient initially received four courses of cell infusions, followed by eight courses of cell therapy plus anti-MDR-TB drugs. Clinical examinations, including clinical response, routine blood tests and biochemical indicators, chest CT imaging, immune cell surface markers, body weight, and sputum Mycobacterium tuberculosis testing, were conducted. Our study revealed that allogeneic V gamma 9V delta 2 T cells are clinically safe for TB therapy. These cells exhibited clinical efficacy in multiple aspects, including promoting the repair of pulmonary lesions, partially improving host immunity, and alleviating M. tuberculosis load in vivo, regardless of their application in the presence or absence of anti-TB drugs. This pilot study opens a new avenue for anti-TB treatment and exhibits allogeneic V gamma 9V delta 2 T cells as promising candidates for developing a novel cell drug for TB immunotherapy.